Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 3:40 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 9,133 matching trials from the live ClinicalTrials.gov search.

Filters: Tampa, Florida Clear all

Conditions: Specific Phobia, Animal
Interventions: Telemedicine-Based Virtual Reality Exposure Therapy, Telemedicine-Based Exposure Therapy Using Photos and Videos; Behavioral
Lead sponsor: University of South Florida; Other
Eligibility: 18 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Tourette Syndrome
Interventions: NBI-98854, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 44
States / cities: Sun City, Arizona • Springdale, Arkansas • Long Beach, California + 41 more

Conditions: Alzheimer Disease
Interventions: Flortaucipir F18, Brain PET Scan; Drug · Procedure
Lead sponsor: Avid Radiopharmaceuticals; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 9
States / cities: San Diego, California • Santa Ana, California • Delray Beach, Florida + 6 more

Conditions: Non-Arteritic Anterior Ischemic Optic Neuropathy
Interventions: Cenegermin, Vehicle; Drug · Other
Lead sponsor: Dompé Farmaceutici S.p.A; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 27
States / cities: Los Angeles, California • Newport Beach, California • Palo Alto, California + 21 more

Conditions: Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified, Recurrent Cervical Carcinoma, Stage IV Cervical Cancer AJCC v6 and v7, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7
Interventions: Atezolizumab, Bevacizumab, Laboratory Biomarker Analysis; Drug · Biological · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 22
States / cities: Los Angeles, California • Pasadena, California • Aurora, Colorado + 13 more

Conditions: Ovarian Cancer
Interventions: OTL38, Near infrared camera imaging system, Laparotomy; Drug · Device · Procedure
Lead sponsor: On Target Laboratories, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Orange, California • Tampa, Florida • Rochester, Minnesota + 1 more

Conditions: Liver Fibrosis Due to NASH
Interventions: Placebo, SIM; Biological
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 41
States / cities: Phoenix, Arizona • Coronado, California • San Diego, California + 34 more

Conditions: Fabry Disease, Fabry Disease, Cardiac Variant
Interventions: ST-920; Biological
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2039
U.S. locations: 8
States / cities: Irvine, California • Tampa, Florida • Atlanta, Georgia + 5 more

Conditions: Colorectal Cancer
Interventions: Capecitabine (Xeloda); Drug
Lead sponsor: James A. Haley Veterans Administration Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Neuroendocrine Tumors, Neuroendocrine Carcinoma, Neuroendocrine Cancer
Interventions: Pembrolizumab, Lenvatinib; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Parkinson's Disease (PD)
Interventions: ABBV-951, Placebo for Levodopa/Carbidopa (LD/CD), Levodopa/Carbidopa (LD/CD), Placebo for ABBV-951; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 30 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 70
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 62 more

Conditions: Bipolar Disorder
Interventions: Aripiprazole, placebo; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 53
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • National City, California + 50 more

Conditions: Graft Versus Host Disease
Interventions: Cultured Treg cells; Biological
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Early Alzheimer's Disease
Interventions: CT1812, Placebo; Drug
Lead sponsor: Cognition Therapeutics; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 540 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 50
States / cities: Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more

Conditions: Tumors, Hematologic Malignancies
Interventions: Atezolizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 661 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2018
U.S. locations: 16
States / cities: Scottsdale, Arizona • Los Angeles, California • Stanford, California + 10 more

Conditions: PTSD
Interventions: TNX-102 SL, Placebo SL Tablets; Drug
Lead sponsor: Tonix Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 192 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 30
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Rogers, Arkansas + 27 more

Conditions: Hypertension
Interventions: Febuxostat, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 45
States / cities: Foley, Alabama • Buena Park, California • Carmichael, California + 42 more

Conditions: Major Depressive Disorder
Interventions: OPC-34712, Placebo, ADT; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 50
States / cities: Arcadia, California • Beverly Hills, California • Escondido, California + 43 more

Conditions: COVID-19
Interventions: AZD7442, Placebo, Remdesivir; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 1,455 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 88
States / cities: Tucson, Arizona • Chula Vista, California • Fresno, California + 59 more

Conditions: Atopic Dermatitis
Interventions: PF-04965842 200 mg, PF-04965842 100 mg, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 9
States / cities: Encinitas, California • Los Angeles, California • Largo, Florida + 5 more

Conditions: Atopic Dermatitis, Eczema
Interventions: Lebrikizumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 6 Months to 18 Years
Enrollment: 338 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 21
States / cities: Birmingham, Alabama • Phoenix, Arizona • North Little Rock, Arkansas + 18 more

Conditions: HR+/HER2- Breast Cancer
Interventions: BGB-43395, Letrozole, Abemaciclib, Palbociclib, Ribociclib; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 1,056 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2037
U.S. locations: 84
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 79 more

Conditions: Hypertension
Interventions: carvedilol, metoprolol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 30 Years to 80 Years
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 119
States / cities: Birmingham, Alabama • Columbia, Alabama • Mobile, Alabama + 97 more

Conditions: Melanoma
Interventions: Relatlimab, Nivolumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 12 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 22
States / cities: Tucson, Arizona • Los Angeles, California • San Luis Obispo, California + 17 more

Search by objective public record fields.

A Randomized Controlled Efficacy Trial of a Telemedicine-based Virtual Reality Clinic for the Treatment of Phobias

Safety and Efficacy Study of NBI-98854 in Children and Adolescents With Tourette Syndrome

Tau Screening Study in Patients With Early Symptomatic AD

Efficacy and Safety of Intranasal Cenegermin in Adult Participants With Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer

Phase 2 Study of OTL38 for Intra-operative Imaging of Folate Receptor-alpha Positive Ovarian Cancer

Safety and Efficacy of Simtuzumab (SIM, GS-6624) in Adults With Advanced Liver Fibrosis But Not Cirrhosis Secondary to Non-Alcoholic Steatohepatitis (NASH)

Long-Term Follow-up of Subjects Who Were Treated With ST-920

Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease

Aripiprazole in Children and Adolescents With Bipolar I Disorder

Ex-vivo Expanded Donor Regulatory T Cells for Prevention of Acute Graft-Versus-Host Disease

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

Effect of Febuxostat on Blood Pressure

Study of the Safety and Efficacy of OPC-34712 as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

AZD7442 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

Study Evaluating the Mechanism of Action of PF-04965842 Monotherapy for Moderate-to-severe Atopic Dermatitis

A Study to Assess the Long-Term Safety and Efficacy of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

Effect Of Carvedilol Versus Metoprolol On Glycemic Control In Patients With Type II Diabetes And Hypertension

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma